Perceptive Advisors Llc Acquires 2,481,350 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) Stock

Astria Therapeutics, Inc. (NASDAQ:ATXSGet Free Report) Director Perceptive Advisors Llc purchased 2,481,350 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were bought at an average price of $12.09 per share, with a total value of $29,999,521.50. Following the purchase, the director now owns 4,873,721 shares in the company, valued at $58,923,286.89. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Perceptive Advisors Llc also recently made the following trade(s):

  • On Thursday, December 21st, Perceptive Advisors Llc purchased 740,000 shares of Astria Therapeutics stock. The shares were bought at an average price of $6.20 per share, with a total value of $4,588,000.00.

Astria Therapeutics Trading Up 6.2 %

ATXS opened at $14.89 on Wednesday. The company has a market cap of $659.85 million, a PE ratio of -6.77 and a beta of 0.68. The company has a 50 day moving average of $7.81 and a 200 day moving average of $7.26. Astria Therapeutics, Inc. has a 12 month low of $4.26 and a 12 month high of $15.70.

Astria Therapeutics (NASDAQ:ATXSGet Free Report) last issued its earnings results on Monday, November 13th. The biotechnology company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.12). Research analysts forecast that Astria Therapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Astria Therapeutics by 473.1% in the second quarter. BlackRock Inc. now owns 1,652,510 shares of the biotechnology company’s stock valued at $13,765,000 after acquiring an additional 1,364,141 shares during the period. Driehaus Capital Management LLC increased its position in shares of Astria Therapeutics by 1.6% in the second quarter. Driehaus Capital Management LLC now owns 1,455,648 shares of the biotechnology company’s stock valued at $12,126,000 after acquiring an additional 22,974 shares during the period. Affinity Asset Advisors LLC increased its position in shares of Astria Therapeutics by 53.7% in the third quarter. Affinity Asset Advisors LLC now owns 1,000,300 shares of the biotechnology company’s stock valued at $7,462,000 after acquiring an additional 349,425 shares during the period. Vanguard Group Inc. increased its position in shares of Astria Therapeutics by 5.5% in the third quarter. Vanguard Group Inc. now owns 531,153 shares of the biotechnology company’s stock valued at $4,802,000 after acquiring an additional 27,743 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Astria Therapeutics during the first quarter valued at about $6,463,000. Hedge funds and other institutional investors own 87.85% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ATXS shares. Oppenheimer decreased their price target on shares of Astria Therapeutics from $30.00 to $25.00 and set an “outperform” rating for the company in a research note on Wednesday, November 15th. Wedbush reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Astria Therapeutics in a report on Tuesday, January 30th. Finally, HC Wainwright cut their price objective on shares of Astria Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, October 12th.

Get Our Latest Report on Astria Therapeutics

Astria Therapeutics Company Profile

(Get Free Report)

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema.

Recommended Stories

Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.